Sitka Partners: Turning Rain into Gold

Sitka aims to help young companies realize their potential through offering both advice and early-stage finance. It's latest fund focuses on continental Europe.

The strong, lightweight timber of the North American Sitka spruce is so valuable that the tree became known for turning rain into gold. When entrepreneur Louis Nisbet, PhD, and venture capitalist Gérard Tardy founded Sikta Partners three years ago, it was to help young companies in the UK and European health care sector extract similar value from their resources through offering strategy and fundraising advice. As biotechs start to emerge from their harshest funding winter in years, "our aim is to help groups clearly think through their strategy and how to deliver on it, and to make sure they get enough capital, at each fundraising, to make a significant difference within the company before they need to go back for more," explains Nisbet, who also founded biotech firm Xenova Group PLC .

Sitka's target audience: 2-3 year old firms, mostly in the UK and France, operating within what has become known as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.